It’s MS, Emeryville, not you.
That’s the drum Bayer HealthCare is beating as it shifts production of its multiple sclerosis drug Betaseron from Emeryville to a European contract manufacturer over the next two years.
Who’s to blame? Surely not Emeryville or the 540 employees of the East Bay facility, said Bayer spokesman Sreejit Mohan. Instead, health system reform worldwide and an increasingly competitive market for MS drugs are putting pressure on Bayer and other MS drug companies.